2024    2023    2022    2021    2020    2019    2018    2017    2016   

2022

Workshop/conference papers

71 - 

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Arthur Bobin, Jerome Lambert, Stéphanie Ragot, Aurore Perrot, Salomon Manier, Lionel Karlin, Denis Caillot, Cyrille Hulin, Lotfi Benboubker, Carla Araujo et al.

64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States. pp.4452-4453,

DOI : https://doi.org/10.1182/blood-2022-166870

 

72 - 

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status

Olivier Decaux, Radhia Lafore, Daniel Iaquinta, Christina Tekle, Xavier Leleu

64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States. pp.10969-10970,

DOI : https://doi.org/10.1182/blood-2022-162602

 

73 - 

NK-like CD8+T cells with high cytotoxic properties are the reservoir of clonal cells and related to disease activity in multiple sclerosis

E Dugast, I Vogel, E Kervagoet, C Monvoisin, A Garcia, J Morille, S Shah, R Amoriello, M Jacq-Foucher, M Moyon et al.

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Oct 2022, Amsterdam, Netherlands. pp.231-231.

 

74 - 

Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study

Cyrille Hulin, Aurore Perrot, Margaret Macro, Anne Vekhoff, Xavier Leleu, Lionel Karlin, Salomon Manier, Laure Vincent, Abderrazak El Yamani, Wajed Abarah et al.

64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States. pp.7133-7135,

DOI : https://doi.org/10.1182/blood-2022-159424

 

75 - 

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) in real-life context: interim analysis of the retrospective IMAGE study

Xavier Leleu, Radhia Lafore, Daniel Iaquinta, Christina Tekle, Megan Rice, Olivier Decaux

64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States.

 

76 - 

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort Direction du Système d'Information Connexion au réseau wifi eduroam

Aurore Perrot, Olivier Decaux, Bruno Royer, Denis Caillot, Karim Belhadj Merzoug, Agathe Farge, Laurent Frenzel, Cécile Sonntag, Bohrane Slama, Emmanuelle Bourgeois-Petit et al.

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort. 64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States. pp.4379-4381,

DOI : https://doi.org/10.1182/blood-2022-158484

 

77 - 

Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network

Murielle Roussel, Michelle Pirotte, Ornella Rizzo, Kentin Queru, Thomas Chalopin, Olivier Decaux, Estelle Desport, Frank Bridoux, Arnaud Jaccard

64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States. pp.10086-10087,

DOI : https://doi.org/10.1182/blood-2022-166224

 

78 - 

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Bijal Shah, Armin Ghobadi, Olalekan Oluwole, Aaron Logan, Nicolas Boissel, Ryan Cassaday, Thibaut Leguay, Michael Bishop, Max Topp, Dimitrios Tzachanis et al.

64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States. pp.3158-3161,

DOI : https://doi.org/10.1182/blood-2022-158248

 

79 - 

Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chrétien, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab et al.

2022 ASCO Annual Meeting I, Jun 2022, Chicago, United States. pp.8002-8002.